

## SINUVA™ (mometasone furoate) sinus implant

# Office reimbursement guide

### Coding and billing

Possible ICD-10-CM codes <sup>1</sup>	Descriptor
J33.0	Polyp of nasal cavity
J33.1	Polypoid sinus degeneration
J33.8	Other polyp of sinus
J33.9	Nasal polyp, unspecified

  

HCPSC <sup>2</sup>	Billable units	Descriptor
J7402	1 unit for every 10 mcg = 135 billing units	Mometasone furoate sinus implant, (sinuva), 10 micrograms

  

NDC number	Descriptor
10599000301	SINUVA™ (mometasone furoate) 1350 mcg

  

Wholesale acquisition cost (WAC)
\$1474.35

**Multiple procedure modifiers do not apply to HCPSC codes.**

### CPT® codes

Providers should report the CPT code(s) that most accurately describe the services performed in association with placement of a drug-eluting sinus implant.

#### Disclaimer

Medtronic provides this information for your convenience only. It does not constitute legal advice or a recommendation regarding clinical practice. Information provided is gathered from third-party sources and is subject to change without notice due to frequently changing laws, rules and regulations. The provider has the responsibility to determine medical necessity and to submit appropriate codes and charges for the care provided. Medtronic makes no guarantee that the use of this information will prevent differences of opinion or disputes with Medicare or other payers as to the correct form of billing or the amount that will be paid to providers of service. Please contact your Medicare contractor, other payers, reimbursement specialists and/or legal counsel for interpretation of coding, coverage and payment policies. This document provides assistance for FDA approved or cleared indications. Where reimbursement is sought for use of a product that may be inconsistent with, or not expressly specified in, the FDA cleared or approved labeling (e.g. instructions for use, operator's manual or package insert), consult with your billing advisors or payers on handling such billing issues. Some payers may have policies that make it inappropriate to submit claims for such items or related service.

#### INDICATION

SINUVA™ Sinus Implant is a corticosteroid-eluting implant indicated for the treatment of chronic rhinosinusitis with nasal polyps in adult patients ≥ 18 years of age who have had ethmoid sinus surgery.

#### IMPORTANT SAFETY INFORMATION

#### CONTRAINDICATIONS

Patients with known hypersensitivity to mometasone furoate and any of the ingredients of the SINUVA™ Sinus Implant.

**Please see additional important safety information on the next page.**

21. DIAGNOSIS OR NATURE OF ILLNESS OR INJURY Relate A-L to service line below (24E)										ICD-10-CM		22. RESUBMISSION CODE		ORIGINAL REF. NO.													
A. XXX.X		B. _____		C. _____		D. _____		E. _____		F. _____		G. _____		H. _____													
E. _____		F. _____		G. _____		H. _____		I. _____		J. _____		K. _____		L. _____													
24. A. DATE(S) OF SERVICE From MM DD YY To MM DD YY										B. PLACE OF SERVICE		C. EMG		D. PROCEDURES, SERVICES, OR SUPPLIES (Explain Unusual Circumstances) CPT/HCPCS MODIFIER		E. DIAGNOSIS POINTER		F. \$ CHARGES		G. DAYS OR UNITS		H. EPSON PRINTING		I. ID. QUAL.		J. RENDERING PROVIDER ID. #	
1 N410599000301 UN2										11		J7402		A		XXX				NPI							
2 04 01 21										11		XXXXX		A		01				NPI							

### Important safety information (continued)

**Local Nasal Adverse Reactions:** Monitor nasal mucosa adjacent to the SINUVA(TM) Sinus Implant for any signs of bleeding (epistaxis), irritation, infection, or perforation. Avoid use in patients with nasal ulcers or trauma.

Please see additional important safety information on the next page.

## Billing the National Drug Code (NDC)

When billing physician administered drugs with a J Code, payers may require the 11-digit NDC to be included on claims. The 11-digit billable NDC for SINUVA™ (mometasone furoate) sinus implant is **10599000301**.

For proper claim filing this information must be captured in a specific format as shown below.

Electronic claims (ANSI 5010 837)		Loop	Segment
Product ID qualifier	Enter <b>N4</b> in this field	2410	LIN02
National Drug Code	Enter 11-digit NDC <b>10599000301</b>	2410	LIN03
National Drug Code unit count	Enter quantity (number of NDC units) <b>1</b> (unilateral) or <b>2</b> (bilateral)	2410	LIN04
Unit of measure	Enter NDC unit of measure as <b>UN</b> followed by units billed 1 unit = <b>UN1</b>	2410	CTP05

## Obtaining SINUVA™ (mometasone furoate) sinus implant

To order SINUVA™ implant for in-office use, please call the Specialty Distributor Besse Medical at **1-800-543-2111** or McKesson Med Surg at **1-855-571-2100**.

## SINUVA™ Indication & Important Safety Information

### Healthcare Professional Facing Materials

#### INDICATION

SINUVA™ Sinus Implant is a corticosteroid-eluting implant indicated for the treatment of chronic rhinosinusitis with nasal polyps in adult patients ≥ 18 years of age who have had ethmoid sinus surgery.

#### IMPORTANT SAFETY INFORMATION

##### CONTRAINDICATIONS

Patients with known hypersensitivity to mometasone furoate and any of the ingredients of the SINUVA™ Sinus Implant.

##### WARNINGS AND PRECAUTIONS

**Local Nasal Adverse Reactions:** Monitor nasal mucosa adjacent to the SINUVA™ Sinus Implant for any signs of bleeding (epistaxis), irritation, infection, or perforation. Avoid use in patients with nasal ulcers or trauma.

**Glaucoma and Cataracts:** Nasal steroids may result in development of glaucoma and/or cataracts. Glaucoma, cataracts, and clinically significant elevation of intraocular pressure were not observed in patients from the treatment group of one randomized controlled clinical study (N = 53) who underwent bilateral placement of SINUVA™ Sinus Implants. Close monitoring is warranted in patients with a change in vision or with a history of increased intraocular pressure, glaucoma, and/or cataracts.

**Hypersensitivity Reactions:** Hypersensitivity reactions, including rash, pruritus, and angioedema have been reported with the use of corticosteroids.

**Immunosuppression and Risk of Infections:** Persons who are using drugs that suppress the immune system, such as corticosteroids, including SINUVA™ Sinus Implant are more susceptible to infections than healthy individuals. The safety and effectiveness of SINUVA™ Sinus Implant have not been established in pediatric patients less than 18 years of age and SINUVA™ is not indicated for use in this population. Corticosteroids should be used with caution, if at all, in patients with active or quiescent tuberculosis infection of the respiratory tract; untreated systemic fungal, bacterial, viral, or parasitic infections; or ocular herpes simplex.

**Hypercorticism and Adrenal Suppression:** If corticosteroid effects such as hypercorticism and adrenalsuppression appear in patients, consider sinus implant removal.

##### ADVERSE REACTIONS

The most common adverse reactions observed (> 1% of subjects) in clinical studies were asthma, headache, epistaxis, presyncope, bronchitis, otitis media, and nasopharyngitis.

##### POSTMARKETING EXPERIENCE

The following adverse reactions have been identified during post-approval use of the SINUVA™ sinus implant. These events include implant migration, lack of efficacy, nasal pain, headache, epistaxis.

Rx only. Please see Full Prescribing Information for SINUVA™ at [SINUVA.com/PI](https://www.medtronic.com/SINUVA.com/PI).

##### References

1. International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM). <https://www.cms.gov/medicare/coding-billing/icd-10-codes/2024-icd-10-cm>. Accessed July 10, 2024.
2. Healthcare Common Procedure Coding System (HCPCS) Level II codes, including device C-codes, are maintained by the Centers for Medicare and Medicaid Services. <https://www.cms.gov/medicare/coding-billing/healthcare-common-procedure-system/quarterly-update>. Accessed July 10, 2024.

# Medtronic

#### ENT

6743 Southpoint Drive N  
Jacksonville, FL 32216  
USA  
Toll free: 800-874-5797  
Telephone: 904-296-9600  
Fax: 800-678-3995

©2024 Medtronic. Medtronic, Medtronic logo, and Engineering the extraordinary are trademarks of Medtronic. ®Third-party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company.  
10/2024 - US-ENT-2301901 Rev 15.0 - [WFF#13649623]